Invossaの新興薬剤に関する洞察と市場予測：2032年

Invossa（TG-C）は、初代ヒト軟骨細胞（軟骨細胞）と治療用成長因子TGF-B1を発現するように形質転換されたヒト細胞を含む同種（ドナー）細胞・遺伝子治療薬です。Invossa（TG-C）はこの2つの組み合わせです。膝関節OAを治療するために開発され、膝関節内に1回注射することで投与されます。

クラス初の細胞介在型遺伝子治療薬であるTG-C LDは、1回の関節内注射で膝関節OAを治療します。米国におけるTG-C（TG-C LDではない）のライセンス保有者であるKolon TissueGeneは、米国における第II相臨床試験を完了し、初期データとして、膝関節に1回注射するだけで、最大2年間、持続的な疼痛緩和と運動機能改善を実証しました。現在、米国においてTG-Cの安全性と有効性を確認するため、1,020人の患者を対象とした第III相臨床試験が進行中です。さらに、米国第II相臨床試験で観察された統計学的に有意な疼痛軽減と機能改善を確認するため、DMOAD（変形性関節症治療薬）指定に向けた疾患進行の遅延を示す試験が計画されています。

当レポートでは、主要6ヶ国およびカナダにおけるInvossa市場について調査し、市場の概要とともに、2024年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 変形性関節症に対するInvossaの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 Invossa市場評価

• 変形性関節症に対するInvossaの市場展望
• 主要6ヶ国市場およびカナダの分析
  • 主要6ヶ国市場およびカナダにおける変形性関節症に対するInvossaの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国
  • カナダ

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Invossa, Clinical Trial Description, 2023
• Table 2: Invossa, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Invossa Market Size in the 6MM and Canada, in USD million (2019-2032)
• Table 6: Invossa Market Size in the US, in USD million (2019-2032)
• Table 7: Invossa Market Size in Germany, in USD million (2019-2032)
• Table 8: Invossa Market Size in France, in USD million (2019-2032)
• Table 9: Invossa Market Size in Italy, in USD million (2019-2032)
• Table 10: Invossa Market Size in Spain, in USD million (2019-2032)
• Table 11: Invossa Market Size in the UK, in USD million (2019-2032)
• Table 12: Invossa Market Size in Canada, in USD million (2019-2032)

List of Figures

• Figure 1: Invossa Market Size in the 6MM and Canada, USD million (2019-2032)
• Figure 2: Invossa Market Size in the United States, USD million (2019-2032)
• Figure 3: Invossa Market Size in Germany, USD million (2019-2032)
• Figure 4: Invossa Market Size in France, USD million (2019-2032)
• Figure 5: Invossa Market Size in Italy, USD million (2019-2032)
• Figure 6: Invossa Market Size in Spain, USD million (2019-2032)
• Figure 7: Invossa Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Invossa Market Size in Canada, USD million (2019-2032)

“"Invossa Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about invossa for osteoarthritis in the six major markets. A detailed picture of the invossa for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada for the study period 2019 -2032 is provided in this report along with a detailed description of the invossa for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the invossa market forecast analysis for osteoarthritis in the 6MM, along with Canada, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.

Drug Summary:

Invossa (TG-C) is an allogeneic (donor) cell and gene therapy involving primary human chondrocytes (cartilage cells) and human cells transduced to express the therapeutic growth factor TGF-B1. Invossa (TG-C) is a combination of the two. It has been developed to treat knee OA and is delivered via one intra-articular injection into the knee.

A first-in-class cell-mediated gene therapy, TG-C LD targets knee OA through a single intra-articular injection. Kolon TissueGene, the license holder for TG-C in the United States (not TG-C LD), has completed a Phase II clinical trial in the United States, with initial data demonstrating sustained pain relief and mobility improvement following a single injection in the knee joint, for possibly up to 2 years. Phase III clinical trials in the United States comprising 1,020 patients are currently ongoing to confirm the safety and efficacy of TG-C. In addition, to confirm the statistically significant pain reduction and function improvements observed from the US Phase II clinical trial, the trials are designed to show the delay of disease progression to achieve a DMOAD (Disease Modifying Osteoarthritis Drug) designation.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the invossa description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.
• Elaborated details on invossa regulatory milestones and other development activities have been provided in this report.
• The report also highlights the invossa research and development activities in osteoarthritis across the United States, Europe and Canada.
• The report also covers the patents information with expiry timeline around invossa.
• The report contains forecasted sales of invossa for osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.
• The report also features the SWOT analysis with analyst views for invossa in osteoarthritis.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Invossa Analytical Perspective by DelveInsight

• In-depth Invossa Market Assessment

This report provides a detailed market assessment of invossa for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada. This segment of the report provides forecasted sales data from 2024 to 2032.

• Invossa Clinical Assessment

The report provides the clinical trials information of invossa for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence invossa dominance.
• Other emerging products for osteoarthritis are expected to give tough market competition to invossa and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of invossa in osteoarthritis.
• Our in-depth analysis of the forecasted sales data of invossa from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the invossa in osteoarthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of invossa?
• What is the clinical trial status of the study related to invossa in osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the invossa development?
• What are the key designations that have been granted to invossa for osteoarthritis?
• What is the forecasted market scenario of invossa for osteoarthritis?
• What are the forecasted sales of invossa in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada?
• What are the other emerging products available and how are these giving competition to invossa for osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?

Table of Contents

1. Report Introduction

2. Invossa Overview in Osteoarthritis

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Invossa Market Assessment

• 5.1. Market Outlook of Invossa in Osteoarthritis
• 5.2. 6MM and Canada Analysis
  • 5.2.1. Market Size of Invossa in the 6MM and Canada for Osteoarthritis
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Invossa in the United States for Osteoarthritis
  • 5.3.2. Market Size of Invossa in Germany for Osteoarthritis
  • 5.3.3. Market Size of Invossa in France for Osteoarthritis
  • 5.3.4. Market Size of Invossa in Italy for Osteoarthritis
  • 5.3.5. Market Size of Invossa in Spain for Osteoarthritis
  • 5.3.6. Market Size of Invossa in the United Kingdom for Osteoarthritis
  • 5.3.7. Market Size of Invossa in Canada for Osteoarthritis

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options